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Abstract This review summarizes current evidence and rec-
ommendations regarding cow’s milk allergy (CMA), the most
common food allergy in young children, for the primary and
secondary care providers. The diagnostic approach includes
performing a medical history, physical examination, diagnos-
tic elimination diets, skin prick tests, specific IgE measure-
ments, and oral food challenges. Strict avoidance of the
offending allergen is the only therapeutic option. Oral immu-
notherapy is being studied, but it is not yet recommended for
routine clinical practice. For primary prevention of allergy,
exclusive breastfeeding for at least 4 months and up to
6 months is desirable. Infants with a documented hereditary
risk of allergy (i.e., an affected parent and/or sibling) who
cannot be breastfed exclusively should receive a formula with
confirmed reduced allergenicity, i.e., a partially or extensively
hydrolyzed formula, as a means of preventing allergic reac-
tions, primarily atopic dermatitis. Avoidance or delayed intro-
duction of solid foods beyond 4–6 months for allergy preven-
tion is not recommended.
Conclusion: For all of those involved in taking care of
children’s health, it is important to understand the multifaceted
aspects of CMA, such as its epidemiology, presentation, diag-
nosis, and dietary management, as well as its primary
prevention.
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Introduction
Cow’s milk allergy (CMA) is a common diagnosis in infants
and children. It is clearly overdiagnosed in many cases, but it
is also underdiagnosed in many others. Many health care
professionals and parents alike confuse, at times, CMA with
lactose malabsorption. Inappropriate elimination diets have
been imposed on pregnant and lactating women and their
infants to prevent allergies without scientific evidence proving
their efficacy. Even when well indicated in infants and chil-
dren diagnosed with an allergy, the type of dietary products to
eliminate and the duration of such elimination are not always
logical. Elimination of all cow's milk products, without ap-
propriate substitutions, can lead tomalnutrition and/or specific
nutrient deficiencies at a time when infants and children are
growing. For all of those involved in taking care of children’s
health, it is important to understand the multifaceted aspects of
CMA, such as its epidemiology, presentation, diagnosis, and
dietary management, as well as its primary prevention. Rec-
ommended therapeutic modalities should be based on evi-
dence. This is possible whenever enough studies in one par-
ticular area, in homogenous populations, help prove or dis-
prove a certain diagnostic or therapeutic approach.
Here, we discuss current evidence and recommendations
on the prevalence, natural history, clinical manifestations,
diagnosis, management, and prevention of CMA aimed at
the primary and secondary care providers. For this,
MEDLINE was searched in May 2014. Preference was given
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to evidence and recommendations from scientific societies
published in the last 4 years (2010–2014). Documents found
to relate to both food allergy in children in general and CMA
in particular were included. Among the documents found
regarding general allergy are those by the US National Insti-
tute of Allergy and Infectious Diseases (NIAID 2010) [7] and
International Collaboration in Asthma, Allergy and Immunol-
ogy (International Consensus ON, ICON 2012) [9]. Among
those specifically related to CMA are the ones published by
the World Allergy Organization (WAO 2010) [18], the Euro-
pean Society for Paediatric Gastroenterology, Hepatology and
Nutrition (ESPGHAN 2012) [31], and the British Society for
Allergy and Clinical Immunology (BSACI 2014) [36]. Al-
though in this review, we will present the available evidence,
at the end, we will make some comments regarding areas of
doubt that may occur in clinical practice.
Definition
The topic of definition still causes confusion among physi-
cians. Words such as “allergy,” “intolerance,” and “hypersen-
sitivity” are used interchangeably. The accepted definition of
allergy is “a hypersensitivity reaction triggered by specific
immunologic mechanisms” [7, 28, 29] There is no such thing
as “allergy to lactose” but rather lactose intolerance.
Prevalence
Conclusions from a 2010 systematic review concluded that
the evidence for the prevalence of food allergy is greatly
limited by a lack of uniformity of the criteria for making a
diagnosis. Consequently, it remains unclear whether the prev-
alence is increasing [10], although some data suggest it [9].
The prevalence of CMA in children living in the developed
world is approximately 2 to 3 % [25, 56], making it the most
common cause of food allergy in the pediatric population.
Only among breastfed infants is the prevalence lower
(0.5 %) [25]. These numbers most likely refer to IgE-
mediated CMA, while the prevalence of non-IgE-mediated
CMA is not well known.
Principal allergens
The major cow’s allergens belong to the casein fraction of
proteins (αs1-, αs2-, β-, and κ-casein) and to whey proteins
(α-lactalbumin and β-lactoglobulin) [62]. There is some
cross-reactivity with soy protein, particularly in non-IgE-
mediated allergy. There are immune and non-immune-
mediated allergic phenomena. Immune-mediated adverse
food reactions can be classified into four major categories:
IgE-mediated, non-IgE-mediated, mixed, and cell-mediated
reactions [7]. CMA is most frequently caused by a non-IgE-
mediated mechanism.
IgE and non-IgE-mediated allergy
Two basic mechanisms explain allergic reactions to cow’s
milk as well as to other food allergens: those mediated by
IgE and those not mediated by IgE. The most common IgE-
mediated manifestations of CMA are acute urticaria and an-
gioedema. The most common non-IgE-mediated manifesta-
tions of CMA are involving skin and the gastrointestinal tract.
At the level of the gastrointestinal tract, presentations include
the following: (1) CM-induced enterocolitis syndrome which
involves the entire gastrointestinal tract, (2) CM-induced en-
teropathy that involves only the small bowel, and (3) CM-
induced proctitis and proctocolitis, involving the rectum and
colon [18].
Clinical manifestations
CMA is mostly a disease of infancy and early childhood.
Affected infants present usually within the first 6 months of
life, and one review reported that the majority of infants
develop symptoms before 1 month of age, often within 1 week
after the introduction of cow’s milk proteins to their diet [25].
However, breastfed infants can also be affected by dairy
products ingested by the mother and eliminated in her breast
milk. Rare is the onset of symptoms after 12 months of age
[36]. The majority of affected children have one or more
symptoms involving one or more organ systems, mainly the
gastrointestinal tract and/or skin. One recent review suggests
that gastrointestinal food allergies are commonly associated
with a wide range of extra-intestinal manifestations such as
f a t i gue , a l l e rg i c sh i ne r s , mou th u l c e r s , j o i n t
pain/hypermobility, poor sleep, night sweats, headache, and
bed wetting [13].
Symptoms of non-IgE-mediated CMA are mostly delayed
reactions that occur beyond 2 h following ingestion) and
usually involve the gastrointestinal tract and/or skin [54].
Symptoms such as urticaria and/or angioedema with vomiting
and/or wheezing are suggestive of IgE-mediated CMA, which
generally occur within minutes and up to 2 h of cow’s milk
protein ingestion. The skin is frequently involved followed by
the gastrointestinal tract and, least frequently, the respiratory
and/or cardiovascular systems. The majority of reactions are
mild to moderate, but life-threatening anaphylaxis (1–2 %)
can also occur [36, 53] (Table 1). Together with peanuts and
tree nuts, cow’s milk is one of themost common foods capable
of causing anaphylactic reactions [27]. Evidence of sensitiza-
tion (presence of specific IgE) is typical [53].
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Other IgE-mediated disorders include food protein-induced
enterocolitis syndrome (the entire gastrointestinal tract is in-
volved), food protein-induced enteropathy (small bowel),
food protein-induced proctitis and proctocolitis (rectum and
colon), and food-induced pulmonary hemosiderosis (Heiner’s
syndrome) [53]. Mixed IgE- and non-IgE-mediated reactions,
involving humoral and/or cell-mediated mechanisms, also
manifest themselves at the level of the skin and/or gastroin-
testinal tract. Such entities include allergic eosinophilic gas-
trointestinal disorders and atopic dermatitis (eczema).
CMA is generally outgrown during early childhood or, at
the latest, in adolescence. Overall, the chances of outgrowing
an allergy are better for non-IgE-mediated CMA. Children at
risk of not resolving the problem are those affected with IgE-
mediated CMA who have high levels of milk-specific IgE
antibodies, multiple food allergies, and/or concomitant asthma
and allergic rhinitis. Such children are more likely to have a
more prolonged persistence of sensitization [36, 51]. Greater
chances of developing tolerance to cow’s milk were found in
children with low levels of IgE binding to cow’s milk and
specific IgE binding to α-lactalbumin, β-lactoglobulin, κ-
casein, and αs1-casein [1]. Resolution of CMAwithin the first
5 years of life could be predicted by milk-specific IgE levels,
skin prick test results, and the severity of atopic dermatitis
[63]. A web-based calculator to determine the prognosis of
children with CMA is available at www.cofargroup.org.
Validation studies are still needed [36].
Diagnosis
Among other organizations, ESPGHAN has developed an
algorithm for the evaluation of infants and children with
symptoms compatible with the diagnosis of CMA (Fig. 1).
In addition to the detailed medical history and physical exam-
ination, diagnostic elimination diets, skin prick tests (SPTs),
specific IgE (sIgE) measurements, and oral food challenges
are part of the routine work-up [7, 18, 31, 53]. If the patient is
in the appropriate age range and the history and symptoms are
consistent with the diagnosis of CMA, an open or single-blind




Time of exposure to reaction Minutes to 2 h Several hours to days
Severity Mild to anaphylaxis Mild to moderate
Duration May persist beyond 1 year of age Usually resolved by 1 year
Diagnosis Specific serum IgE, skin prick tests Oral challenge
Fig. 1 Evaluation of infants
suspected of having cow’s milk
protein allergy (CMP) according
to the ESPGHAN criteria
(Koletzko et al. [31], permission
obtained). eHF extensively
hydrolyzed formula AAF amino
acid-based formula
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challenge is often sufficient to make the diagnosis. However, a
double-blind, placebo-controlled oral food challenge is still
the gold standard for the diagnosis of food allergy [50]. When
cow’s milk protein is the only suspected allergen, the diagno-
sis is simpler than on cases where the child is already ingesting
a variety of foods.Whenmultiple food allergies are suspected,
published standards for office-based oral food challenges [40],
as well as for double-blind, placebo-controlled, oral food
challenges, should be followed [49].
A systematic review published recently looked into
the specificity and sensitivity of tests employed for the
diagnosis of food allergy. Results indicate that the
existing evidence regarding the accuracy of such tests
is limited, making their interpretation problematic [58].
In IgE-mediated food allergy, determination of SPT and
sIgE seems to be sensitive, albeit not specific. For the
specific case of IgE-mediated CMA, the values are as
follows: sIgE, sensitivity 87 % (75 to 94) and specific-
ity 48 % (36 to 59); SPT, sensitivity 88 % (76 to 94)
and specificity 68 % (56 to 77). In non-IgE-mediated
CMA, the value of tests is far more limited, and the
clinician needs to rely on history, physical examination,
and the results of the elimination diet and relapse upon
milk challenge. The offending food challenge is the
diagnostic gold standard [36]. Screening tests, such as
SPTs, sIgE tests, and atopy patch tests, have been
shown to lack specificity and sensitivity [7]. On the
other hand, tests such as Vega (electrodermal), or cyto-
toxicity, iridology, kinesiology, food-specific IgG, pulse,
and hair analysis are not recommended for the diagnosis
of allergy because of the lack of any scientific evidence
and reliability and reproducibility [9, 36]. Fecal studies
for food particles or immune components are not reli-
able either.
Management of cow’s milk allergy
Avoidance of cow’s milk protein in any form is the only
available treatment [14, 21, 36]. In the case of breastfed
infants, the mother should eliminate all dairy products from
her own diet. It has to be considered that it may take up to 72 h
to clear breast milk antigens ingested by the lactating woman.
Calcium supplements should be added to the mother’s diet to
replace milk intake [18, 31, 36]. From the practical standpoint,
treatment of CMA imposes less sacrifices on the mother if the
child was not being breastfed, provided that the family is
given access or can afford the cost of special infant formulas.
For infants 6 months old or younger, the recommended for-
mulas for treatment of CMA are extensively hydrolyzed pro-
tein or amino acid-based formula. In infants older than
6 months, soy formula could be tried particularly in IgE-
mediated cases.
Which formula and to whom
Extensively hydrolyzed formulas
The American Academy of Pediatrics defines as “extensively
hydrolyzed formula” those containing only oligopeptides that
have a molecular weight <3,000 Da to which at least 90 % of
infants do not manifest any clinical symptoms in controlled
double-blind studies [21]. Initial exclusive feeding of an ex-
tensively hydrolyzed formula is the treatment of choice for
infants suspected of having CMA suffering from mild to
moderate disease (see below). Because of its taste, some
children may refuse to take the needed quantities for growth
in which case an amino acid-based formula may be needed as
their organoleptic characteristics are not as unpleasant.
Amino acid formulas
These formulas, as the name indicates, provide protein only in
the form of free amino acids and no peptides. Although in
theory, amino acid formulas may be used as first-line treat-
ment for CMA, their high cost may be a limiting factor.
BSACI recommendations [36] for amino acid formulas in-
clude the following: infants and children with (1) severe CMA
(failure to thrive and abundant blood in stools), (2) multiple
food allergies, (3) allergic symptoms or severe atopic eczema
when exclusively breastfed, (4) severe forms of non-IgE-
mediated CMA, such as eosinophilic esophagitis, enteropa-
thies, and food protein-induced enterocolitis syndrome, (5)
growth faltering, and/or (6) infants at nutritional risk with
reactions to or refusal to ingest appropriate amounts of exten-
sively hydrolyzed formula.
Amino acid formula vs. extensively hydrolyzed whey
or casein formula
An amino acid rather than an extensively hydrolyzed formula
is recommended for infants with IgE-mediated CMA at high
risk of anaphylactic reactions (prior history of anaphylaxis and
currently not receiving extensively hydrolyzed protein formu-
la). Extensively hydrolyzed protein formula rather than an
amino acid formula is recommended for infants with IgE-
mediated CMA at low risk of anaphylactic reactions (no prior
history of anaphylaxis or currently receiving an extensively
hydrolyzed protein formula) [31, 36].
Soy protein formula
The North American Society for Pediatric Gastroenterology,
Hepatology and Nutrition and ESPGHAN recommendations
agree that soy formulas should not be used in infants with food
allergy under 6 months of age. Because of their lower cost and
better palatability than extensively hydrolyzed formulas, soy
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protein formulas could be considered for use in patients with
food allergy older than 6 months of age. In such cases,
however, tolerance to soy protein should first be established
by clinical challenge. Infants with IgE-mediated CMA allergy
are more likely to tolerate soy formula than those with non-
IgE-mediated CMA [6, 14].
Extensively hydrolyzed whey or casein formula vs. soy
formula
Use of extensively hydrolyzed milk formula rather than soy
formula is recommended in infants with IgE-mediated CMA.
Soy formula is not recommended in infants under 6 months of
age [6, 14].
Extensively hydrolyzed whey or casein formula vs.
extensively hydrolyzed rice formula
Although tolerance and safety of an extensively hydrolyzed
rice protein-based formula compared with those of an exten-
sively hydrolyzed cow’s milk protein-based formula are now
available [61], existing recommendations favor the use of the
latter, in children with IgE-mediated CMA (one of the reasons
being its almost worldwide availability).
Soy formula vs. extensively hydrolyzed rice formula
Currently, no extensive data are available.
Partially hydrolyzed formula
The American Academy of Pediatrics defines partially
hydrolyzed formulas as those containing reduced pro-
portion of peptides with a molecular weight greater than
5,000 Da [21]. These formulas should not be used for
the treatment of suspected or proven CMA or for the
diagnostic exclusion diet.
Other milks
Preparations based on unmodified milk of milks from other
mammalian species (sheep, buffalo, horse, camel, or goat
milk) or unmodified soy or rice milk should not be used to
treat CMA because of their high rate of possible allergenic
cross-reactivity and insufficient nutritional value [18]. Simi-
larly, “milk beverages,” derived from almond, coconut, hazel-
nut, oat, potato, rice, or soya, are not recommended because of
their nutritional inadequacy. Compared with cow’s milk, most
of them are low in energy and extremely low in protein [36].
Need for calcium
Calcium supplementation (also phosphorus and vitamin D) is
not generally necessary in infants ingesting sufficient amounts
of special formula. Whenever milk intake is below 500 ml,
assessment by a pediatric dietitian is recommended, and Ca
supplement may be needed [36].
Growth and nutritional concerns
Cow’s milk exclusion diets without appropriate substitution
may lead to nutritional deficiencies and poor growth [38].
Discomfort from the underlying illness such as atopic derma-
titis or feeding difficulties due to esophageal dysmotility in
eosinophilic esophagitis may further contribute to inadequate
nutrient intake. Considering these concerns, scientific organi-
zations recommend the use of an age-appropriate milk substi-
tute in children younger than 2 years of age and food counsel-
ing. Isolauri et al. analyzed 100 infants with a mean age of
7 months with a diagnosis of atopic dermatitis and challenge-
proven CMA who were evaluated for growth during the
therapeutic elimination diet [26]. Although clinical control
of symptoms was achieved in all patients, mean length SD
score and weight-for-length index of patients decreased com-
pared with those of healthy age-matched children, p<0.0001
and p=0.03, respectively. In addition, low serum albumin was
seen in 6 %, abnormal urea concentration in 24 %, and low
serum phospholipid docosahexaenoic acid in 8 %. The delay
in growthwas more pronounced in a subgroup of patients with
early onset than in those with later of symptoms.
Duration of milk exclusion diet
Once an infant is diagnosed as having CMA and is placed on
an exclusion diet, reevaluation needs to be performed every
6 months if the child is under 1 year of age and every 6–
12months from 1 year of age onward, to determine if the child
is a candidate for reintroducing cow’s milk. The BSACI has
suggested an escalation of products, a so-called “milk ladder,”
starting with baked milk products, as thermal processing
reduces allergenicity [36]. If well tolerated, more allergenic
products can be reintroduced progressively leaving for the end
uncooked cheese and fresh cow’s milk, which should only be
introduced in children with demonstrated full tolerance to
baked milk products.
Introduction of complementary food
The earlier recommendations of avoidance or delayed intro-
duction of potentially allergenic foods have been replaced by
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guidelines recommending exactly the opposite. Several pro-
spective birth cohort studies such as GINI [17], LISA [65],
KOALA [57], and Generation R [59] indicated no obvious
effect of the delayed introduction of solid foods on the prev-
alence of food allergies. More recently, a population-based,
cross-sectional study, which involved 2,589 infants, found
that, regardless of eczema status, delayed dietary introduction
of egg was associated with a higher risk of egg allergy [32].
Cooked eggs (i.e., boiled, scrambled, fried, or poached) rather
than baked eggs (egg-containing products such as cakes or
biscuits) at 4 to 6 months of age were more effective in
preventing the development of egg allergy at 1 year of age.
This finding would point out to the importance of the way that
a food item is prepared in addition to the time at which it is
introduced.
At present, there is a lack of convincing scientific evidence
indicating that delayed introduction of potentially allergenic
foods (e.g., cow’s milk protein [except for whole cow’s milk],
eggs, peanuts, tree nuts, fish, and seafood) beyond 4–6months
reduces allergies in infants considered to be at increased risk
for the development of allergic diseases. Highly allergenic
foods are best first introduced at home, rather than at a day
care center or at a restaurant [20].
Probiotics
The WAO recently concluded that, as of today, no single
probiotic supplement or combination of them has shown to
dramatically influence the course of allergic manifestations or
long-term outcome in a permanent way [19]. One randomized
controlled trial (RCT) published subsequently to the WAO
document found that the addition of Lactobacillus rhamnosus
GG (LGG) to the therapeutic formula has an impact on acqui-
sition of tolerance. In this trial particpants were randomly
assigned to receive one of the following formulas: extensively
hydrolyzed casein, extensively hydrolyzed casein with LGG,
hydrolyzed rice, soy, or amino acid-based [4]. The rate of oral
tolerance after 1-year treatment determined by food challenge
was significantly higher in the groups that received extensive-
ly hydrolyzed casein formula whether it was with LGG
(78.9 %) or without (43.6 %) compared with the other groups:
hydrolyzed rice formula (32.6 %), soy formula (23.6 %), and
amino acid-based formula (18.2%) Repeat studies are needed.
Induction of oral tolerance
At present, there are no established guidelines or protocols on
how to proceed with this aspect of treatment. Once an elimi-
nation diet is in place and the patient improves, the next major
challenge is the induction of tolerance. Reasoning behind the
use of the oral route is to expose the immune system to either
low doses of antigen or to antigenically modified molecules,
capable of inducing a response of immunotolerance without
one of allergy. As shown in two meta-analyses, compared to
an elimination diet alone, oral immunotherapy for IgE-
mediated CMA showed improved chances of achieving
CM’s tolerance [8, 64]. However, those two meta-analyses
also showed that development of long-term tolerance was
unlikely. Oral immunotherapy, however, poses the risk of
severe adverse reactions. Experience, however, indicates that
when reactions occur, these are generally mild and short
lasting. A possible form of oral immunotherapy could
be the use of extensively heated milk as well as egg
protein because studies have shown that the protein
treated in such manner may be tolerated by children
who react to raw cow milk [30, 35]. Although studies
are still limited, experts have suggested that an oral
challenge under professional supervision using heated
milk could be tried in children with CMA. Guidelines
still do not recommend the use of baked milk products
for desensitization in routine clinical practice.
There is a potential role for probiotics in inducing
immunotolerance. A study of the effect of certain probiotic
strains on tolerance acquisition in children with CMA gave
negative results [24]. However, Berni-Canani et al. [3] ran-
domly allocated infants with CMAwhile still receiving intact
protein formula to a group that received either extensively
hydrolyzed casein formula or the same EHCF containing
Lactobacillus GG. After 6 months of an exclusion diet, a
double-blind placebo-controlled milk challenge was per-
formed in 55 patients, and evidence of tolerance was seen in
21.4 and 59.3 %, respectively. The difference in acquisition of
immunotolerance was significant only for those children with
non-IgE-mediated CMA (p=0.017).
Prevention of cow’s milk allergy
It could be hypothesized that allergen avoidance during the
first few months of life, period of immune immaturity, could
be beneficial in allergy prevention. However, evidence points
otherwise.
Diet during pregnancy or lactation
The available data do not support cow’s milk antigen
avoidance, and therefore, specific allergen avoidance is
not recommended during pregnancy [20, 53]. Still under
investigation is whether that recommendation also applies
to peanut [37, 55]. The negative impact of dietary restric-
tions on the nutrition of the pregnant woman and her fetus
also needs to be considered when eliminating ubiquitous
nutrients.
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Breastfeeding
The mechanisms by which exclusive breastfeeding may help
in the prevention of allergic disease are passive and active:
passive, by decreasing exposure to exogenous antigens, and
active, by providing substances present in breast milk capable
of protecting the infant against infections, inducingmaturation
of the gastrointestinal mucosa, promoting the development of
healthy gut microbiota, and conferring immunomodulatory
and anti-inflammatory benefits [52].
Although the idea that breast milk is effective for
allergy prevention is very logical, scientific evidence
demonstrating such beneficial effects is not always sup-
portive [15]. Many factors play a role in making such
demonstration difficult, reflecting a variety of methodo-
logical problems related with investigating breastfeeding
in studies. These include inability to randomize and
blind, the retrospective design of many studies and the
potential for parental recall bias, imprecise definitions of
the intervention with no clear distinction between “ex-
clusive breastfeeding” and “any breastfeeding,” the lack
of strict diagnostic criteria for allergic diseases, and,
finally, reverse causation, meaning that mothers of in-
fants who show evidence of allergy may continue to
breastfeed longer to prevent worsening of symptoms.
The Despite the controversy, exclusive breastfeeding
for at least 4 months, but preferentially up to 6 months
is recommended [15, 21, 52].
Dietary products with reduced allergenicity
In the following section, we discuss options for those infants
who are not going to be breastfed or in whom breastfeeding
will be supplemented with formula.
Hydrolyzed formula
A summary article of reviews and a systematic review of
subsequently published trials reported that certain extensively
hydrolyzed casein formulas and certain partially hydrolyzed
whey formulas are capable of reducing the risk of allergy in
high-risk infants [60]. Thus, in high-risk infants who are not
being breastfed, hydrolysates of documented safety and effi-
cacy have an indication for infant feeding up to the age of 4 to
6 months. Current recommendations also agree that infants
with a documented hereditary risk of allergy (i.e., an affected
parent and/or sibling) who are not exclusively breastfed would
also benefit from such formulas as a means of preventing
allergic reactions, primarily atopic dermatitis [7, 16]. There
are no data regarding allergy prevention by special infant
formulas in the not-at-risk population.
Soy protein formula
Compared with cow’s milk formula, soy formula failed to
prevent allergy in later infancy and childhood in infants at
high risk of allergy who were not completely breastfed, as
shown in one meta-analysis of three RCTs [43]. Therefore,
soy protein formula has no role for the prevention of allergic
diseases [6, 14].
Amino-acid-based formula
There are no studies using amino-acid-based formulas for
allergy prevention.
Probiotics and/or prebiotics
Several recent meta-analyses have suggested that certain
probiotics administered both prenatally and postnatally are
effective in preventing eczema [5, 35, 45]. An important
limitation of such studies, however, is that all of them pooled
data from studies in which different probiotic strains were
used, lacking subanalyses to determine effects of individual
probiotic strain(s). The World Allergy Organization has con-
cluded that in view of the existing information, probiotics do
not have a proven role in the prevention of allergy [19]. The
evidence supporting prebiotics and synbiotics positively af-
fecting the development and severity of allergic disease is
even weaker [22, 33, 44].
Long-chain polyunsaturated fatty acids
The balance between pro-inflammatory n-6 long-chain poly-
unsaturated fatty acid (LCPUFA) and anti-inflammatory n-3
LCPUFA may play a role in the development of allergy.
Epidemiological data support the knowledge that low con-
sumption of oily fish rich in n-3 LCPUFA favors the presence
of more n-6 LCPUFA and contributes to the development of
allergy and asthma [23, 42]. However, a 2008 meta-analysis
of ten publications (representing six RCTs) found no clear
evidence of a benefit of n-3 or n-6 supplementation for reduc-
tion of the risk of allergic sensitization or developing a favor-
able immunological profile [2]. However, the impact of
LCPUFA supplementation may only have a window. Studies
suggest that the timing of the intervention may play an im-
portant role. The Docosahexaenoic Acid to Optimise Mother
Infant Outcome (DOMInO) RCT found that maternal n-3
LCPUFA supplementation (900 mg/day) during pregnancy
reduced the risk of atopic eczema and egg sensitization during
the first year of life but not the overall incidence of IgE-
associated allergies [46].
Postnatal supplementation with n-3 LCPUFA has shown
mixed results: One study suggested a transient effect on
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symptoms of respiratory disease [39], while another showed
no effect [11].
Other nutritional interventions
Supportive evidence is weak with respect to supplementation
with vitamins A, D, and E; zinc; fruit and vegetables; and a
Mediterranean diet for the prevention of atopic disease, name-
ly, asthma as concluded by a recent systematic review and
meta-analysis of observational trials (no RCTs were identi-
fied) [41]. At present, no specific recommendations exist for
the doses and timing of these products for allergy prevention.
Management of anaphylaxis
One recent systematic review found no robust studies inves-
tigating the effectiveness of adrenaline (epinephrine), H1 anti-
histamines, systemic glucocorticosteroids, or methylxanthines
in the management of anaphylaxis [12].
Even if the evidence is limited, the first-line treatment for
anaphylaxis is epinephrine (both in the outpatient setting
[autoinjector] and in a hospital setting). Other medications
used in the management of anaphylaxis include anti-
histamines or anti-inflammatory drugs (systemic or topical
steroids) [7]. The latter are the main therapy in cases of
eosinophilic esophagitis or gastroenteritis in which dietary
restriction was not feasible or had failed to improve the disease
[48].
What it is that is not in the guidelines
Infants suspected of having CMA who are not breastfed are
placed on a special infant formula for up to 6 weeks (depend-
ing on the symptoms) and then challenged. If they do not
relapse, they are considered to be either cured or that the
diagnosis was incorrect. However, CMA may relapse with
symptoms that are different from those seen at presentation.
One form of CMA is enteritis which may lead to nutrient
malabsorption. It is recommended that infants be followed
closely for growth parameters following reintroduction of
cow’s milk to their diet.
Another caveat is that infants with CMAmay have delayed
gastric emptying and present with vomiting hours after having
ingested milk or food. In evaluating infants experiencing
vomiting and considering gastroesophageal reflux, it has to
be kept in mind that in simple gastroesophageal reflux,
vomiting occurs during or immediately after a meal
(30 min), while vomiting that occurs hours after a meal may
be associated to allergy. Ravelli et al. described that in
sensitized infants, cow’s milk induces severe gastric dysrhyth-
mia and delayed gastric emptying, which, in turn, may exac-
erbate GER and induce reflex vomiting [47].
Summary
In this article, we review current recommendations regarding
CMA, which is the most common food allergy in infants and
young children. A medical history including history of allergy
in close relatives, physical examination, and diagnostic elim-
ination diets are the first steps for the accurate diagnosis and
management of these patients. sIgE measurements, SPTs, and
oral food challenges are usually performed to determine if the
problem is IgE-mediated or not. Strict avoidance of the
offending allergen is the only therapeutic option. Recommen-
dations for the primary prevention of allergy include exclusive
breastfeeding for at least 4 months and up to 6 months if
possible. Infants with a documented hereditary risk of allergy
(i.e., an affected parent and/or sibling) who cannot be exclu-
sively breastfed should receive a formula with confirmed
reduced allergenicity, i.e., a partially or extensively hydro-
lyzed as a way to minimize the risk of allergic reactions,
primarily atopic dermatitis. There is no evidence that avoid-
ance or delayed introduction of solid foods beyond 4–
6 months has a positive effect for allergy prevention.
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